GlassScriptPhysician profile
Gloria P Simms
NPI 1164651352
$234,196.86
in general payments reported to CMS, 2019-2025
21 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $14K · 2021: $34K · 2022: $31K · 2023: $35K · 2024: $24K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Consulting Fee: $7,650 · Travel and Lodging: $7,561 · Food and Beverage: $2,786 · Education: $24.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,824.00 |
| Consulting Fee | $7,650.00 |
| Travel and Lodging | $7,561.34 |
| Food and Beverage | $2,786.49 |
| Education | $24.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $87,890.36 | 2019-2022 | |
| Abbvie INC. | $68,327.99 | 2019-2025 | Qulipta, Ubrelvy |
| Pfizer International LLC | $20,382.25 | 2023 | |
| Pfizer INC. | $18,147.34 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13,987.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $8,831.18 | 2021 | |
| Allergan, INC. | $8,544.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $6,177.84 | 2019-2021 | |
| Lundbeck LLC | $420.89 | 2023-2025 | Vyepti |
| Lilly USA, LLC | $284.25 | 2019-2025 | Emgality, Kisunla |
| Supernus Pharmaceuticals, INC. | $269.64 | 2019-2020 | |
| Ucb, INC. | $185.41 | 2019 | |
| Argenx US, INC. | $125.00 | 2023 | Vyvgart |
| Biogen, INC. | $121.20 | 2019 | |
| Eisai INC. | $115.23 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $100.39 | 2021 | |
| Alexion Pharmaceuticals, INC. | $96.35 | 2019 | |
| Neurocrine Biosciences, INC. | $84.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $46.72 | 2019-2023 | |
| Mdd US Operations, LLC | $34.94 | 2019 | |
| Impel Pharmaceuticals INC. | $24.32 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Simms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.